Valuation : Soligenix, Inc.

Market Cap 8.27M 7.12M 6.7M 6.12M 11.44M 781M 11.47M 79.13M 30.7M 401M 31.06M 30.38M 1.29B P/E 2026 *
-0.69x
P/E 2027 * -0.95x
Enterprise Value 8.27M 7.12M 6.7M 6.12M 11.44M 781M 11.47M 79.13M 30.7M 401M 31.06M 30.38M 1.29B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
95.41%
Yield 2026 *
-
Yield 2027 * -
1 day-0.84%
1 week+0.85%
1 month+0.80%
3 months-20.98%
6 months-67.52%
Current year-71.64%
1 week 0.36
Extreme 0.3589
0.39
1 month 0.36
Extreme 0.3589
0.42
Current year 0.28
Extreme 0.28
1.49
1 year 0.28
Extreme 0.28
2.98
3 years 0.28
Extreme 0.28
32
5 years 0.28
Extreme 0.28
295.2
10 years 0.28
Extreme 0.28
2,040
Manager TitleAgeSince
Chief Executive Officer 59 01/08/2006
Director of Finance/CFO 53 11/09/2019
Chief Tech/Sci/R&D Officer - 11/06/2026
Director TitleAgeSince
Chairman 59 08/10/2009
Director/Board Member 67 01/03/2009
Director/Board Member 80 01/10/2009
Date Insider Type Main position Quantity % Market Cap. Importance
11/12/25 Free

Chief Executive Officer

200,000 1.9829%
11/12/25 Free

Chief Technology Officer

100,000 0.9915%
11/12/25 Free

Chief Technology Officer

10,000 0.0991%
Change 5-day change 1-year change 3-year change Capi.($)
-0.84%+0.85%-87.50%-94.58% 8.27M
-1.79%-2.27%+50.90%+89.03% 67.98B
-2.06%-0.18%+41.53%+88.17% 64.94B
-0.31%+6.54%-11.39%+457.82% 27.58B
-3.00%-2.90%+39.40%+9.41% 25.74B
+0.86%+1.65%+0.25%-14.78% 26.06B
-1.46%+0.42%+24.07%-18.70% 20.09B
-2.96%-15.21%+210.71%+370.84% 17.16B
-1.49%-4.88%-0.41%+530.26% 14.92B
-0.20%+8.37%+57.87%+159.50% 14.62B
Average -1.32%+0.32%+32.54%+157.70% 27.91B
Weighted average by Cap. -1.52%+0.18%+42.29%+145.07%

Financials

2026 *2027 *
Net sales - -
Net income -9.3M -8M -7.53M -6.88M -12.87M -878M -12.9M -88.97M -34.53M -451M -34.92M -34.16M -1.45B -10.1M -8.69M -8.18M -7.47M -13.97M -954M -14.01M -96.63M -37.5M -489M -37.93M -37.1M -1.58B
Net Debt - -
Logo Soligenix, Inc.
Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).
Employees
14
Date Price Change Volume
04/09/26 USD 0.3800 -0.84% 119,098
03/09/26 USD 0.3832 +0.39% 59,964
02/09/26 USD 0.3817 +1.52% 93,558
01/09/26 USD 0.3760 -1.05% 122,718
31/08/26 USD 0.3800 +0.85% 404,158
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.3800USD
Average target price
1.375USD
Spread / Average Target
+261.84%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SNGX Stock